News: 2019
Aglaia Oncology Funds and Sinzer - Grant Thornton Launch Dedicated Life Sciences Impact Measuring and Reporting Suite
December 19, 2019
• Enables visibility for investors of social impact realized by their investments
• Suite demonstrates value beyond financial...
Read more
InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual OTS meeting
October 31, 2019
InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual...
Read more
Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors
September 26, 2019
Macrophage Pharma Limited has appointed Dr. Anker Lundemose as independent non-executive director.
Read more
Macrophage Pharma appoints Dr Søren Bregenholt as Chief Executive Officer
September 03, 2019
Macrophage Pharma Limited ('MPL') announced today that it has appointed Dr Søren Bregenholt as Chief Executive Officer....
Read more
Cristal Therapeutics appoints Dr Werner Cautreels as a new Director and Board Chairman and Andre Verwei as Chief Financial Officer
August 01, 2019
Maastricht, The Netherlands, 1st August 2019 - Cristal Therapeutics, a Phase 2 clinical stage pharmaceutical company developing...
Read more
Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial
August 01, 2019
AMSTERDAM--(BUSINESS WIRE)--Modra Pharmaceuticals B.V. ("Modra") today announced the start of patient treatment in its Phase II...
Read more
Cristal Therapeutics to present data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on lead clinical candidate CPC634 in patients with solid tumors
May 17, 2019
Cristal Therapeutics, a clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and...
Read more
InteRNA and UMC Utrecht Publish Preclinical Evidence for Potential of miRNAs in Treatment of Epilepsy
May 15, 2019
- Journal of Neuroscience publication demonstrates that antagonizing
miR-135a reduces seizures in chronic TLE model -
Read more
A One-Two Punch for HPV-16-positive Cancers? 30 Apr 2019
April 30, 2019
ISA's phase 2 trial with lead product ISA101
Read more
Video interview with ISA CSO Prof. Dr. Cornelis Melief at AACR 2019
April 18, 2019
ecancer interview ISA's Chief Science Officer Prof. Dr. Kees Melief
Read more
CRI Speaks with 2019 AACR-CRI Lloyd J. Old Award Recipient, Dr. Cornelis 'Kees' Melief
April 02, 2019
Cornelis J. M. 'Kees' Melief, M.D., Ph.D., received the 2019 AACR-CRI Lloyd J. Old Award in Cancer Immunology presented by the...
Read more
ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeting 2019
March 28, 2019
- Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation
Read more
InteRNA Appoints Andrea van Elsas, Ph.D. to Scientific Advisory Board
March 25, 2019
--Co-inventor of original CTLA4-antibody and immuno-oncology innovator to expand the Company's clinical development expertise--...
Read more
Modra Pharmaceuticals announces first patients treated in phase IIa metastatic breast cancer trial
March 21, 2019
Drug Name : docetaxel + ritonavir
Read more
ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Cornelis Melief Receives AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019
March 19, 2019
- Recognition for outstanding and innovative cancer research
Read more
Sapreme Technologies in a 6.8 M€ EU Alliance to Develop an Oligonucleotide Delivery Platform Based on Its Proprietary Endosomal Escape Enhancers
February 20, 2019
Sapreme Technologies has been awarded a 6.8 M€ grant by the European Union.
Read more
